Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Sep 15;7(9):e610.
doi: 10.1038/bcj.2017.76.

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival

M Chin  1 , J I Sive  2 , C Allen  1 , C Roddie  1 , S J Chavda  1 , D Smith  1 , P Blombery  3 , K Jones  3 , G L Ryland  3 , R Popat  1 , A Rismani  4 , S D'Sa  4 , N Rabin  4 , R E Gale  1 , K L Yong  1
Affiliations
Clinical Trial

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival

M Chin et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Clinical impact of TP53 mutations. (a) Swimmer plot displaying the time of del(17p) FISH testing/detection and TP53 mutation screening for each TP53-mutated patient. Kaplan–Meier curves for (b) overall survival (OS) from first detection of del(17p) in patients with and without TP53 mutations, and (c) from first detection of the mutation in TP53-mutated patients compared to the last time point tested in non-mutated patients. Dotted Line, TP53-mutated patients; solid line, non-TP53 patients. CI, 95% confidence intervals; HR, hazard ratios.
See this image and copyright information in PMC

References

    1. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Huilin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. Blood 2007; 109: 3489–3495. - PubMed
    1. Chng WJ, Price-Troska T, Gonzalez-Paz N, Van Wier S, Jacobus S, Blood E et al. Clinical significance of TP53 mutation in myeloma. Leukemia 2007; 21: 582–584. - PubMed
    1. Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer 2011; 50: 765–774. - PubMed
    1. Fonseca R, Bergasel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer 2011; 50: 765–774. - PubMed
    1. Bergsagel PL, Mateos M-V, Gutierrez NC, Rajkumar SV, San Miguel JF. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood 2013; 121: 884–892. - PMC - PubMed

Substances